Search
for
Sort by
Research 31–60 of 1000+
- Baricitinib Provides Significant Hair Regrowth In Adolescents With Severe Alopecia Areata: 52-Week Efficacy and Safety Results From A Phase 3 Randomized, Controlled Trial
- Efficacy and safety of tofacitinib in pediatric patients with alopecia areata: A prospective cohort study
- Janus kinase inhibitors in dermatology: A systematic review
- Safety and Efficacy of Bimatoprost Solution 0.03% Topical Application in Patients with Chemotherapy-Induced Eyelash Loss
- Safety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment
- Off-label dermatologic uses of IL-23 inhibitors
- Unraveling Ritlecitinib: an in-depth analysis of JAK3 inhibitor for the treatment of alopecia areata
- 42004 Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- 75993 Safety of Janus kinase inhibitors for treatment of alopecia areata
- Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
- Long‐term efficacy and safety of baricitinib in patients with severe alopecia areata: 104‐week results from BRAVE‐AA1 and BRAVE‐AA2
- Evaluation of the Efficacy and Safety of Oral Tofacitinib for the Treatment of Alopecia Areata in Children
- 42736 Safety Assessments in the Multinational Phase 3 THRIVE-AA1 Trial with CTP-543 (Deuruxolitinib) in Adult Patients with Moderate to Severe Alopecia Areata
- Scalp, eyebrow, and eyelash hair regrowth with continued ritlecitinib treatment among patients with alopecia areata without target efficacy response at Week 24: post hoc analysis of the ALLEGRO phase 2b/3 study
- Upadacitinib for Severe Alopecia Areata in Adults and Adolescents
- BH19 ‘JAK in the box?’ Long-term safety concerns with oral Janus kinase inhibitors for alopecia areata
- Therapeutic potential of oral tofacitinib in alopecia areata: a retrospective study
- Novel investigational drugs for alopecia areata and future perspectives
- 1614 A systematic review and meta-analysis of comorbidities in lichen sclerosus with a screening recommendation
- Long-term symptom profiles after COVID-19<i>vs</i>other acute respiratory infections: a population-based observational study (COVIDENCE UK)
- Immunological aspects and gender bias during respiratory viral infections including novel Coronavirus disease‐19 (COVID‐19): A scoping review
- Symptoms Compatible With Long Coronavirus Disease (COVID) in Healthcare Workers With and Without Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection—Results of a Prospective Multicenter Cohort
- Experimental cutaneous Bacillus anthracis infections in hairless HRS/J mice
- Targeting host cell proteases as a potential treatment strategy to limit the spread of SARS‐CoV‐2 in the respiratory tract
- Hétérogénéité tumorale du cancer de la prostate et infection par le SARS-CoV2 : une relation complexe impliquant les vésicules extracellulaires et le récepteur des androgènes
- Severe Acute SARS-CoV-2 Infection and Long COVID: What Do We Know So Far? New Challenges in Diagnosis and Management
- Research progress of post-acute sequelae after SARS-CoV-2 infection
- Symptom Trajectories and Long-Term Sequelae of COVID-19: A Matched Case–Control Study with Population-Based Controls
- Covid-19, Diagnostic History and Mortality from Medicare 1999-2021, In an All-Cause Mortality Approach
- COVID-19: Pulmonary and Extra Pulmonary Manifestations